Innate immunity and neuroinflammation

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Shastri, Abhishek ^a   Bonifati, Domenico Marco ^b   Kishore, Uday ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CHEMOKINE; COMPLEMENT; COMPLEMENT RECEPTOR; CRYOPYRIN; CYTOKINE; HUMORAL ANTIBODY; INFLAMMASOME; INTERLEUKIN 10; LIGAND; LIPOPOLYSACCHARIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ASTROCYTE; ATHEROSCLEROSIS; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HERPES SIMPLEX VIRUS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INNATE IMMUNITY; MICROGLIA; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA; TRAUMATIC BRAIN INJURY; ANIMAL; CYTOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIGANDS; MICROGLIA; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84880174102     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/342931     Document Type: Review

References (319)

1. Murphy K., Innate Immunity: The First Lines of Defense. Janeway's Immunobiology 2012 8th Abingdon, UK Garland Science, Taylor & Francis Group
2. Saijo K., Glass C. K., Microglial cell origin and phenotypes in health and disease. Nature Reviews Immunology 2011 11 11 775 787 10.1038/nri3086
3. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M. F., Conway S. J., Ng L. G., Stanley E. R., Samokhvalov I. M., Merad M., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010 330 6005 841 845 2-s2.0-78149360132 10.1126/science.1194637
4. Nimmerjahn A., Kirchhoff F., Helmchen F., Neuroscience: resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005 308 5726 1314 1318 2-s2.0-19744380563 10.1126/science.1110647 (Pubitemid 40746128)
5. Sierra A., Encinas J. M., Deudero J. J. P., Chancey J. H., Enikolopov G., Overstreet-Wadiche L. S., Tsirka S. E., Maletic-Savatic M., Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 2010 7 4 483 495 2-s2.0-77957328867 10.1016/j.stem.2010.08.014
6. Vinet J., Weering H. R., Heinrich A., Kalin R. E., Wegner A., Brouwer N., Neuroprotective function for ramified microglia in hippocampal excitotoxicity. Journal of Neuroinflammation 2012 9 27 10.1186/1742-2094-9-27
7. Paolicelli R. C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Synaptic pruning by microglia is necessary for normal brain development. Science 2011 333 6048 1456 1458 10.1126/science.1202529
8. Schafer D. P., Lehrman E. K., Kautzman A. G., Koyama R., Mardinly A. R., Yamasaki R., Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012 74 4 691 705 10.1016/j.neuron.2012.03. 026
9. Kettenmann H., Hanisch U. K., Noda M., Verkhratsky A., Physiology of microglia. Physiological Reviews 2011 91 2 461 553 10.1152/physrev.00011.2010
10. Olson J. K., Miller S. D., Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. The Journal of Immunology 2004 173 6 3916 3924 2-s2.0-4644232615 (Pubitemid 39280755)
11. Von Zahn J., Möller T., Kettenmann H., Nolte C., Microglial phagocytosis is modulated by pro-and anti-inflammatory cytokines. NeuroReport 1997 8 18 3851 3856 2-s2.0-0031583918 (Pubitemid 28027197)
12. Sriram K., Matheson J. M., Benkovic S. A., Miller D. B., Luster M. I., O'Callaghan J. P., Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF- The FASEB Journal 2006 20 6 670 682 2-s2.0-33646255922 10.1096/fj.05-5106com (Pubitemid 44933311)
13. Combs C. K., Colleen Karlo J., Kao S. C., Landreth G. E., β -amyloid stimulation of microglia anti monocytes results in TNF -dependent expression of inducible nitric oxide synthase and neuronal apoptosis. The Journal of Neuroscience 2001 21 4 1179 1188 2-s2.0-0035866060 (Pubitemid 32128763)
14. Barcia C., Ros C. M., Annese V., Gómez A., Ros-Bernal F., Aguado-Year C., Martínez-Pa ǵ n M. E., De Pablos V., Fernandez-Villalba E., Herrero M. T., IFN- γ signaling, with the synergistic contribution of TNF- mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death and Disease 2011 2 4, article e142 2-s2.0-79959977446 10.1038/cddis.2011.17
15. Basu A., Krady J. K., Levison S. W., Interleukin-1: a master regulator of neuroinflammation. Journal of Neuroscience Research 2004 78 2 151 156 2-s2.0-4744352557 10.1002/jnr.20266 (Pubitemid 39313786)
16. Shaftel S. S., Griffin W. S. T., Kerry K. M., The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. Journal of Neuroinflammation 2008 5, article 7 2-s2.0-42649084052 10.1186/1742-2094-5-7 (Pubitemid 351597462)
17. Pascual O., Ben Achour S., Rostaing P., Triller A., Bessis A., Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proceedings of the National Academy of Sciences of the United States of America 2012 109 4 E197 E205 10.1073/pnas.1111098109
18. Constam D. B., Philipp J., Malipiero U. V., Ten Dijke P., Schachner M., Fontana A., Differential expression of transforming growth factor- β 1,-β 2, and-β 3 by glioblastoma cells, astrocytes, and microglia. The Journal of Immunology 1992 148 5 1404 1410 2-s2.0-0026541255
19. Lodge P. A., Sriram S., Regulation of microglial activation by TGF- β IL-10, and CSF-1. Journal of Leukocyte Biology 1996 60 4 502 508 2-s2.0-0029956457 (Pubitemid 26356776)
20. Williams K., Dooley N., Ulvestad E., Becher B., Antel J. P., IL-10 production by adult human derived microglial cells. Neurochemistry International 1996 29 1 55 64 2-s2.0-0030198917 10.1016/0197-0186(95)00138-7 (Pubitemid 26276504)
21. Rivest S., Regulation of innate immune responses in the brain. Nature Reviews Immunology 2009 9 6 429 439 2-s2.0-66449130960 10.1038/nri2565
22. Glezer I., Rivest S., Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 2004 10 6 538 552 2-s2.0-9144250527 10.1177/1073858404263494 (Pubitemid 39546396)
23. Nadeau S., Rivest S., Glucocorticoids play a fundamental role in protecting the brain during innate immune response. The Journal of Neuroscience 2003 23 13 5536 5544 2-s2.0-0038722154 (Pubitemid 36807829)
24. Sorrells S. F., Caso J. R., Munhoz C. D., Sapolsky R. M., The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 2009 64 1 33 39 2-s2.0-70349835170 10.1016/j.neuron.2009.09.032
25. Schroder K., Tschopp J., The Inflammasomes. Cell 2010 140 6 821 832 2-s2.0-77950362382 10.1016/j.cell.2010.01.040
26. Halle A., Hornung V., Petzold G. C., Stewart C. R., Monks B. G., Reinheckel T., Fitzgerald K. A., Latz E., Moore K. J., Golenbock D. T., The NALP3 inflammasome is involved in the innate immune response to amyloid- β Nature Immunology 2008 9 8 857 865 2-s2.0-47849085872 10.1038/ni.1636
27. Shi F., Yang L., Kouadir M., Yang Y., Wang J., Zhou X., The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation. Journal of Neuroinflammation 2012 9 73 10.1186/1742-2094-9-73
28. Webster S. D., Park M., Fonseca M. I., Tenner A. J., Structural and functional evidence for microglial expression of C1qR(p), the C1q receptor that enhances phagocytosis. Journal of Leukocyte Biology 2000 67 1 109 116 2-s2.0-0033972658 (Pubitemid 30046825)
29. Matyash V., Kettenmann H., Heterogeneity in astrocyte morphology and physiology. Brain Research Reviews 2010 63 1-2 2 10 2-s2.0-77952422253 10.1016/j.brainresrev.2009.12.001
30. Halassa M. M., Haydon P. G., Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annual Review of Physiology 2009 72 335 355 2-s2.0-77951929051 10.1146/annurev-physiol-021909-135843
31. Henneberger C., Papouin T., Oliet S. H. R., Rusakov D. A., Long-term potentiation depends on release of d-serine from astrocytes. Nature 2010 463 7278 232 236 2-s2.0-74549135360 10.1038/nature08673
32. Halassa M. M., Florian C., Fellin T., Munoz J. R., Lee S. Y., Abel T., Haydon P. G., Frank M. G., Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron 2009 61 2 213 219 2-s2.0-58549112040 10.1016/j.neuron.2008.11.024
33. Suzuki A., Stern S. A., Bozdagi O., Huntley G. W., Walker R. H., Magistretti P. J., Alberini C. M., Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011 144 5 810 823 2-s2.0-79952305803 10.1016/j.cell.2011.02.018
34. Sofroniew M. V., Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences 2009 32 12 638 647 2-s2.0-70449678738 10.1016/j.tins.2009.08.002
35. Farina C., Aloisi F., Meinl E., Astrocytes are active players in cerebral innate immunity. Trends in Immunology 2007 28 3 138 145 2-s2.0-33847099936 10.1016/j.it.2007.01.005 (Pubitemid 46283692)
36. Lieberman A. P., Pitha P. M., Shin H. S., Shin M. L., Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proceedings of the National Academy of Sciences of the United States of America 1989 86 16 6348 6352 2-s2.0-0001139213 (Pubitemid 19210649)
37. van Neerven S., Nemes A., Imholz P., Regen T., Denecke B., Johann S., Beyer C., Hanisch U. K., Mey J., Inflammatory cytokine release of astrocytes in vitro is reduced by all-trans retinoic acid. Journal of Neuroimmunology 2010 229 1-2 169 179 2-s2.0-78650211872 10.1016/j.jneuroim.2010.08.005
38. Johnstone M., Gearing A. J. H., Miller K. M., A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. Journal of Neuroimmunology 1999 93 1-2 182 193 2-s2.0-0032891616 10.1016/S0165-5728(98)00226-4 (Pubitemid 29051564)
39. Garwood C. J., Pooler A. M., Atherton J., Hanger D. P., Noble W., Astrocytes are important mediators of A β -induced neurotoxicity and tau phosphorylation in primary culture. Cell Death and Disease 2011 2 6, article e167 2-s2.0-79959945013 10.1038/cddis.2011.50
40. Sofroniew M. V., Vinters H. V., Astrocytes: biology and pathology. Acta Neuropathologica 2010 119 1 7 35 2-s2.0-77649189116 10.1007/s00401-009-0619-8
41. Barreto G. E., Gonzalez J., Capani F., Morales L., Chang R. C. C., Role of astrocytes in neurodegenerative diseases. Neurodegenerative Diseases-Processes, Prevention, Protection and Monitoring 2011 InTech. http://www.intechopen.com/books/neurodegenerative-diseases-processes-prevention- protection-and-monitoring/role-of-astrocytes-in-neurodegenerative-diseases
42. Kawai T., Akira S., Signaling to NF- B by toll-like receptors. Trends in Molecular Medicine 2007 13 11 460 469 10.1016/j.molmed.2007.09.002 (Pubitemid 350086981)
43. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity. Cell 2006 124 4 783 801 2-s2.0-32944464648 10.1016/j.cell.2006.02.015 (Pubitemid 43261452)
44. O'Neill L. A. J., Bowie A. G., The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology 2007 7 5 353 364 2-s2.0-34247566510 10.1038/nri2079 (Pubitemid 46674493)
45. Ozinsky A., Underhill D. M., Fontenot J. D., Hajjar A. M., Smith K. D., Wilson C. B., Schroeder L., Aderem A., The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proceedings of the National Academy of Sciences of the United States of America 2000 97 25 13766 13771 2-s2.0-0034610291 10.1073/pnas.250476497
46. Oosting M., Ter Hofstede H., Sturm P., Adema G. J., Kullberg B. J., van der Meer J. W., TLR1/TLR2 heterodimers play an important role in the recognition of borrelia spirochetes. PLoS ONE 2011 6 10 e25998 10.1371/journal.pone.0025998
47. Leulier F., Lemaitre B., Toll-like receptors-taking an evolutionary approach. Nature Reviews Genetics 2008 9 3 165 178 2-s2.0-39449112512 10.1038/nrg2303 (Pubitemid 351271799)
48. Siednienko J., Gajanayake T., Fitzgerald K. A., Moynagh P., Miggin S. M., Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN- β and RANTES production. The Journal of Immunology 2011 186 4 2514 2522 2-s2.0-79951835542 10.4049/jimmunol.1003093
49. Liu X., Zhan Z., Li D., Xu L., Ma F., Zhang P., Yao H., Cao X., Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nature Immunology 2011 12 5 416 424 2-s2.0-79954997147 10.1038/ni.2015
50. Yuk J. M., Shin D. M., Lee H. M., Kim J. J., Kim S. W., Jin H. S., The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by toll-like receptors. Nature Immunology 2011 12 8 742 751
51. Jabara H. H., McDonald D. R., Janssen E., Massaad M. J., Ramesh N., Borzutzky A., DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nature Immunology 2012 13 6 612 620
52. Wang X., Loram L. C., Ramos K., de Jesus A. J., Thomas J., Cheng K., Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences of the United States of America 2012 109 16 6325 6330 10.1073/pnas.1200130109
53. Pais T. F., Figueiredo C., Peixoto R., Braz M. H., Chatterjee S., Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway. Journal of Neuroinflammation 2008 5, article 43 2-s2.0-54949148770 10.1186/1742-2094-5-43
54. Bolanle F., Yongshan M., Maria S., Modinat L., Hallenbeck J., Downstream toll-like receptor signaling mediates adaptor-specific cytokine expression following focal cerebral ischemia. Journal of Neuroinflammation 2012 9 174 10.1186/1742-2094-9-174
55. Lin S., Yin Q., Zhong Q., Lv F. L., Zhou Y., Li J. Q., Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. Journal of Neuroinflammation 2012 9 46 10.1186/1742-2094-9-46
56. Liu S., Kielian T., MyD88 is pivotal for immune recognition of Citrobacter koseri and astrocyte activation during CNS infection. Journal of Neuroinflammation 2011 8, article 35 2-s2.0-79955100786 10.1186/1742-2094-8-35
57. Drouin-Ouellet J., Gibrat C., Bousquet M., Calon F., Kriz J., Cicchetti F., The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. Journal of Neuroinflammation 2011 8 137 10.1186/1742-2094-8-137
58. Zheng Z., Yuan R., Song M., Huo Y., Liu W., Cai X., The toll-like receptor 4-mediated signaling pathway is activated following optic nerve injury in mice. Brain Research 2012 1489 90 97 10.1016/j.brainres.2012.10.014
59. Trudler D., Frenkel D., Farfara D., Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators of Inflammation 2010 2010 12 2-s2.0-77956802559 10.1155/2010/497987 497987
60. Cole J. E., Georgiou E., Monaco C., The expression and functions of toll-like receptors in atherosclerosis. Mediators of Inflammation 2010 2010 18 2-s2.0-77955412192 10.1155/2010/393946 393946
61. Tsan M. F., Gao B., Endogenous ligands of Toll-like receptors. Journal of Leukocyte Biology 2004 76 3 514 519 2-s2.0-4344627821 10.1189/jlb.0304127 (Pubitemid 39129081)
62. Beg A. A., Endogenous ligands of Toll-like receptors: Implications for regulating inflammatory and immune responses. Trends in Immunology 2002 23 11 509 512 2-s2.0-0036839577 10.1016/S1471-4906(02)02317-7 (Pubitemid 35223541)
63. Lacroix S., Feinstein D., Rivest S., The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathology 1998 8 4 625 640 2-s2.0-0031683603 (Pubitemid 28460922)
64. Quan N., Whiteside M., Kim L., Herkenham M., Induction of inhibitory factor B mRNA in the central nervous system after peripheral lipopolysaccharide administration: an in situ hybridization histochemistry study in the rat. Proceedings of the National Academy of Sciences of the United States of America 1997 94 20 10985 10990 2-s2.0-0030924057 10.1073/pnas.94.20.10985 (Pubitemid 27430847)
65. Zanoni I., Ostuni R., Marek L. R., Barresi S., Barbalat R., Barton G. M., CD14 controls the LPS-induced endocytosis of toll-like receptor 4. Cell 2011 147 4 868 880 10.1016/j.cell.2011.09.051
66. Glezer I., Chernomoretz A., David S., Plante M. M., Rivest S., Genes involved in the balance between neuronal survival and death during inflammation. PLoS ONE 2007 2 3, article e310 2-s2.0-55849129973 10.1371/journal.pone.0000310
67. Glezer I., Simard A. R., Rivest S., Neuroprotective role of the innate immune system by microglia. Neuroscience 2007 147 4 867 883 2-s2.0-34547127632 10.1016/j.neuroscience.2007.02.055 (Pubitemid 47102534)
68. Harms A. S., Lee J. K., Nguyen T. A., Chang J., Ruhn K. M., Trevino I., Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 2012 60 2 189 202 10.1002/glia.21254
69. Jack C. S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., Shapiro A., Antel J. P., TLR signaling tailors innate immune responses in human microglia and astrocytes. The Journal of Immunology 2005 175 7 4320 4330 2-s2.0-25444498280 (Pubitemid 41361966)
70. Packard A. E., Leung P. Y., Vartanian K. B., Stevens S. L., Bahjat F. R., Stenzel-Poore M. P., TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning. Journal of Cerebral Blood Flow & Metabolism 2012 32 12 2193 2200 10.1038/jcbfm.2012.140
71. Hyakkoku K., Hamanaka J., Tsuruma K., Shimazawa M., Tanaka H., Uematsu S., Akira S., Inagaki N., Nagai H., Hara H., Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010 171 1 258 267 2-s2.0-77957858212 10.1016/j.neuroscience.2010.08.054
72. Rolls A., Shechter R., London A., Ziv Y., Ronen A., Levy R., Schwartz M., Toll-like receptors modulate adult hippocampal neurogenesis. Nature Cell Biology 2007 9 9 1081 1088 2-s2.0-34548358816 10.1038/ncb1629 (Pubitemid 47338146)
73. Ma Y., Li J., Chiu I., Wang Y., Sloane J. A., Lü J., Kosaras B., Sidman R. L., Volpe J. J., Vartanian T., Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. The Journal of Cell Biology 2006 175 2 209 215 2-s2.0-33750333015 10.1083/jcb.200606016 (Pubitemid 44631415)
74. Okun E., Griffioen K., Barak B., Roberts N. J., Castro K., Pita M. A., Cheng A., Mughal M. R., Wan R., Ashery U., Mattson M. P., Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 35 15625 15630 2-s2.0-77957255968 10.1073/pnas.1005807107
75. Kaul D., Habbel P., Derkow K., Kruger C., Franzoni E., Wulczyn F. G., Expression of toll-like receptors in the developing brain. PLoS ONE 2012 7 5 e37767 10.1371/journal.pone.0037767
76. McKernan D. P., Dennison U., Gaszner G., Cryan J. F., Dinan T. G., Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry 2011 1 8 e36 10.1038/tp.2011.37
77. Zimmerman G., Shaltiel G., Barbash S., Cohen J., Gasho C. J., Shenhar-Tsarfaty S., Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NF B pathway. Transl Psychiatry 2012 2 e78 10.1038/tp.2012.4
78. Klein M., Obermaier B., Angele B., Pfister H. W., Wagner H., Koedel U., Kirschning C. J., Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. The Journal of Infectious Diseases 2008 198 7 1028 1036 2-s2.0-51849136592 10.1086/591626
79. Letiembre M., Echchannaoui H., Ferracin F., Rivest S., Landmann R., Toll-like receptor-2 deficiency is associated with enhanced brain TNF gene expression during pneumococcal meningitis. Journal of Neuroimmunology 2005 168 1-2 21 33 2-s2.0-25844519833 10.1016/j.jneuroim.2005.06.016 (Pubitemid 41396400)
80. Dutta R., Krishnan A., Meng J., Das S., Ma J., Banerjee S., Morphine modulation of toll-like receptors in microglial cells potentiates neuropathogenesis in a HIV-1 model of coinfection with pneumococcal pneumoniae. The Journal of Neuroscience 2012 32 29 9917 9930 10.1523/JNEUROSCI.0870-12.2012
81. Arpaia N., Godec J., Lau L., Sivick K. E., McLaughlin L. M., Jones M. B., Dracheva T., Peterson S. N., Monack D. M., Barton G. M., TLR signaling is required for salmonella typhimurium virulence. Cell 2011 144 5 675 688 2-s2.0-79952300209 10.1016/j.cell.2011.01.031
82. Morrison L. A., The Toll of herpes simplex virus infection. Trends in Microbiology 2004 12 8 353 356 2-s2.0-3342882858 10.1016/j.tim.2004.06.001 (Pubitemid 38987820)
83. Sørensen L. N., Reinert L. S., Malmgaard L., Bartholdy C., Thomsen A. R., Paludan S. R., TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. The Journal of Immunology 2008 181 12 8604 8612 2-s2.0-58849152815
84. Zhang S. Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., Picard C., Chapgier A., Plancoulaine S., Titeux M., Cognet C., Von Bernuth H., Ku C. L., Casrouge A., Zhang X. X., Barreiro L., Leonard J., Hamilton C., Lebon P., Héron B., Vallée L., Quintana-Murci L., Hovnanian A., Rozenberg F., Vivier E., Geissmann F., Tardieu M., Abel L., Casanova J. L., TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007 317 5844 1522 1527 2-s2.0-34548699323 10.1126/science.1139522 (Pubitemid 47417427)
85. Reinert L. S., Harder L., Holm C. K., Iversen M. B., Horan K. A., Dagnaes-Hansen F., TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice. The Journal of Clinical Investigation 2012 122 4 1368 1376 10.1172/JCI60893
86. Wang T., Town T., Alexopoulou L., Anderson J. F., Fikrig E., Flavell R. A., Toll-like receptor 3 mediates west nile virus entry into the brain causing lethal encephalitis. Nature Medicine 2004 10 12 1366 1373 2-s2.0-11144273976 10.1038/nm1140 (Pubitemid 40022719)
87. Mishra B. B., Gundra U. M., Teale J. M., Toll-like receptors in CNS parasitic infections. Current Topics in Microbiology and Immunology 2009 336 1 83 104 2-s2.0-77951634353 10.1007/978-3-642-00549-7-5
88. Greene J. A., Sam-Agudu N., John C. C., Opoka R. O., Zimmerman P. A., Kazura J. W., Toll-like receptor polymorphisms and cerebral malaria: TLR2 Δ22 polymorphism is associated with protection from cerebral malaria in a case control study. Malaria Journal 2012 11 47 10.1186/1475-2875-11-47
89. Franklin B. S., Ishizaka S. T., Lamphier M., Gusovsky F., Hansen H., Rose J., Zheng W., Ataíde M. A., De Oliveira R. B., Golenbock D. T., Gazzinelli R. T., Therapeutical targeting of nucleic acid-sensing toll-like receptors prevents experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 2011 108 9 3689 3694 2-s2.0-79952753327 10.1073/pnas.1015406108
90. Zhu X., Pan Y., Li Y., Jiang Y., Shang H., Gowda D. C., Targeting toll-like receptors by chloroquine protects mice from experimental cerebral malaria. International Immunopharmacology 2012 13 4 392 397 10.1016/j.intimp. 2012.05.012
91. Michaud J. P., Richard K. L., Rivest S., MyD88-adaptor protein acts as a preventive mechanism for memory deficits in a mouse model of Alzheimer's disease. Molecular Neurodegeneration 2011 6 1, article 5 2-s2.0-78651367839 10.1186/1750-1326-6-5
92. Michaud J. P., Richard K. L., Rivest S., Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease. Stem Cell Reviews and Reports 2012 8 3 898 904 10.1007/s12015-012-9356-9
93. Hao W., Liu Y., Liu S., Walter S., Grimm M. O., Kiliaan A. J., Penke B., Hartmann T., Rübe C. E., Menger M. D., Fassbender K., Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain 2011 134 1 278 292 2-s2.0-78650687363 10.1093/brain/awq325
94. 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. The Journal of Neuroscience 2008 28 22 5784 5793 2-s2.0-45949106077 10.1523/JNEUROSCI.1146-08.2008
95. Reed-Geaghan E. G., Savage J. C., Hise A. G., Landreth G. E., CD14 and toll-like receptors 2 and 4 are required for fibrillar A β -stimulated microglial activation. The Journal of Neuroscience 2009 29 38 11982 11992 2-s2.0-70349323417 10.1523/JNEUROSCI.3158-09.2009
96. Tang S. C., Lathia J. D., Selvaraj P. K., Jo D. G., Mughal M. R., Cheng A., Siler D. A., Markesbery W. R., Arumugam T. V., Mattson M. P., Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β -peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Experimental Neurology 2008 213 1 114 121 2-s2.0-49349097868 10.1016/j.expneurol.2008.05.014
97. Song M., Jin J., Lim J. E., Kou J., Pattanayak A., Rehman J. A., Kim H. D., Tahara K., Lalonde R., Fukuchi K. I., TLR4 mutation reduces microglial activation, increases A β deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. Journal of Neuroinflammation 2011 92 2-s2.0-79961134149 10.1186/1742-2094-8-92
98. Herber D. L., Roth L. M., Wilson D., Wilson N., Mason J. E., Morgan D., Gordon M. N., Time-dependent reduction in A β levels after intracranial LPS administration in APP transgenic mice. Experimental Neurology 2004 190 1 245 253 2-s2.0-5044222305 10.1016/j.expneurol.2004.07.007 (Pubitemid 39335723)
99. Scholtzova H., Kascsak R. J., Bates K. A., Boutajangout A., Kerr D. J., Meeker H. C., Mehta P. D., Spinner D. S., Wisniewski T., Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. The Journal of Neuroscience 2009 29 6 1846 1854 2-s2.0-60849137841 10.1523/JNEUROSCI.5715-08.2009
100. Doi Y., Mizuno T., Maki Y., Jin S., Mizoguchi H., Ikeyama M., Doi M., Michikawa M., Takeuchi H., Suzumura A., Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease. American Journal of Pathology 2009 175 5 2121 2132 2-s2.0-73649137143 10.2353/ajpath.2009.090418
101. Iribarren P., Chen K., Hu J., Gong W., Cho E. H., Lockett S., Uranchimeg B., Wang J. M., CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2. The FASEB Journal 2005 19 14 2032 2034 2-s2.0-28744458578 10.1096/fj.05-4578fje (Pubitemid 41759755)
102. Kang J., Rivest S., MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. The Journal of Cell Biology 2007 179 6 1219 1230 2-s2.0-37249011467 10.1083/jcb.200705046 (Pubitemid 350277740)
103. Liu Y., Hao W., Dawson A., Liu S., Fassbender K., Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. The Journal of Biological Chemistry 2009 284 6 3691 3699 2-s2.0-63649152262 10.1074/jbc.M804446200
104. Zhao W., Beers D. R., Henkel J. S., Zhang W., Urushitani M., Julien J. P., Appel S. H., Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010 58 2 231 243 2-s2.0-73149105494 10.1002/glia.20919
105. Beraud D., Maguire-Zeiss K. A., Misfolded alpha-synuclein and toll-like receptors: therapeutic targets for parkinson's disease. Parkinsonism & Related Disorders 2012 1 S17 S20 10.1016/S1353-8020(11)70008-6
106. Spinner D. S., In S. C., Seung Y. P., Jae I. K., Meeker H. C., Ye X., LaFauci G., Kerr D. J., Flory M. J., Bo S. K., Kascsak R. B., Wisniewski T., Levis W. R., Schuller-Levis G. B., Carp R. I., Park E., Kascsak R. J., Accelerated prion disease pathogenesis in toll-like receptor 4 signaling-mutant mice. Journal of Virology 2008 82 21 10701 10708 2-s2.0-55249083798 10.1128/JVI.00522-08 (Pubitemid 352691158)
107. Sethi S., Lipford G., Wagner H., Kretzschmar H., Postexposure prophylaxis against prion disease with a stimulator of innate immunity. The Lancet 2002 360 9328 229 230 2-s2.0-0037143011 10.1016/S0140-6736(02)09513-2 (Pubitemid 34804655)
108. Prinz M., Heikenwalder M., Schwarz P., Takeda K., Akira S., Aguzzi A., Prion pathogenesis in the absence of toll-like receptor signalling. The EMBO Reports 2003 4 2 195 199 2-s2.0-0037297956 10.1038/sj.embor.embor731 (Pubitemid 36322162)
109. Chauhan V. S., Sterka D. G., Furr S. R., Marriott I., NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia 2009 57 4 414 423 2-s2.0-66249089027 10.1002/glia.20770
110. Bajramovic J. J., Regulation of innate immune responses in the central nervous system. CNS & Neurological Disorders Drug Targets 2011 10 1 4 24 2-s2.0-79960973055
111. Areschoug T., Gordon S., Scavenger receptors: role in innate immunity and microbial pathogenesis. Cellular Microbiology 2009 11 8 1160 1169 2-s2.0-67650102353 10.1111/j.1462-5822.2009.01326.x
112. Wilkinson K., El Khoury J., Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. International Journal of Alzheimer's Disease 2012 2012 10 489456 10.1155/2012/489456
113. Furr S. R., Chauhan V., Sterka D., Grdzelishvili V., Marriott I., Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. Journal of NeuroVirology 2008 14 6 503 513 2-s2.0-69949122511 10.1080/13550280802337217
114. Crehan H., Hardy J., Pocock J., Microglia, alzheimer's disease, and complement. International Journal of Alzheimer's Disease 2012 2012 983640 10.1155/2012/983640
115. Lee Y. B., Nagai A., Kim S. U., Cytokines, chemokines, and cytokine receptors in human microglia. The Journal of Neuroscience Research 2002 69 1 94 103 2-s2.0-0036644961 10.1002/jnr.10253 (Pubitemid 34734169)
116. Tambuyzer B. R., Ponsaerts P., Nouwen E. J., Microglia: gatekeepers of central nervous system immunology. Journal of Leukocyte Biology 2009 85 3 352 370 2-s2.0-61449224570 10.1189/jlb.0608385
117. Poltorak A., He X., Smirnova I., Liu M. Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 5396 2085 2088 2-s2.0-0032509295 10.1126/science.282.5396.2085 (Pubitemid 29001265)
118. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., Modlin R. L., Akira S., Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. The Journal of Immunology 2002 169 1 10 14 2-s2.0-0036644042 (Pubitemid 34686113)
119. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S., Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999 11 4 443 451 2-s2.0-0033213590 10.1016/S1074-7613(00)80119-3 (Pubitemid 29504199)
120. Takeuchi O., Kawai T., Mühlradt P. F., Morr M., Radolf J. D., Zychlinsky A., Takeda K., Akira S., Discrimination of bacterial lipoproteins by Toll-like recepttor 6. International Immunology 2001 13 7 933 940 2-s2.0-0034922923 (Pubitemid 32685205)
121. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C. J., Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. The Journal of Biological Chemistry 1999 274 25 17406 17409 2-s2.0-0033580949 10.1074/jbc.274.25.17406 (Pubitemid 29283245)
122. Sato M., Sano H., Iwaki D., Kudo K., Konishi M., Takahashi H., Takahashi T., Imaizumi H., Asai Y., Kuroki Y., Direct binding of toll-like receptor 2 to Zymosan, and Zymosan-induced NF- B activation and TNF- secretion are down-regulated by lung collectin surfactant protein A. The Journal of Immunology 2003 171 1 417 425 2-s2.0-0038205797 (Pubitemid 36745315)
123. Alexopoulou L., Holt A. C., Medzhitov R., Flavell R. A., Recognition of double-stranded RNA and activation of NF- B by Toll-like receptor 3. Nature 2001 413 6857 732 738 2-s2.0-0035909372 10.1038/35099560 (Pubitemid 33009951)
124. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S., Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004 303 5663 1526 1529 2-s2.0-1542317578 10.1126/science.1093620 (Pubitemid 38314424)
125. Diebold S. S., Kaisho T., Hemmi H., Akira S., Reis E Sousa C., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004 303 5663 1529 1531 2-s2.0-1542317550 10.1126/science.1093616 (Pubitemid 38314425)
126. Hayashi F., Smith K. D., Ozinsky A., Hawn T. R., Yi E. C., Goodlett D. R., Eng J. K., Akira S., Underhill D. M., Aderem A., The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001 410 6832 1099 1103 2-s2.0-0035953543 10.1038/35074106 (Pubitemid 32391041)
127. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S., A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 6813 740 745 2-s2.0-0034619794 10.1038/35047123 (Pubitemid 32015992)
128. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012 485 7397 251 255 10.1038/nature10992
129. Liu S., Liu Y., Hao W., Wolf L., Kiliaan A. J., Penke B., TLR2 is a primary receptor for alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. The Journal of Immunology 2012 188 3 1098 1107 10.4049/jimmunol.1101121
130. Stewart C. R., Stuart L. M., Wilkinson K., Van Gils J. M., Deng J., Halle A., Rayner K. J., Boyer L., Zhong R., Frazier W. A., Lacy-Hulbert A., Khoury J. E., Golenbock D. T., Moore K. J., CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nature Immunology 2010 11 2 155 161 2-s2.0-75649087741 10.1038/ni.1836
131. Henning L. N., Azad A. K., Parsa K. V. L., Crowther J. E., Tridandapani S., Schlesinger L. S., Pulmonary surfactant protein a regulates TLR expression and activity in human macrophages. The Journal of Immunology 2008 180 12 7847 7858 2-s2.0-50949109278
132. Murakami S., Iwaki D., Mitsuzawa H., Sano H., Takahashi H., Voelker D. R., Akino T., Kuroki Y., Surfactant protein a inhibits peptidoglycan-induced tumor necrosis factor- secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2. The Journal of Biological Chemistry 2002 277 9 6830 6837 2-s2.0-0036510531 10.1074/jbc.M106671200 (Pubitemid 34953065)
133. Ohya M., Nishitani C., Sano H., Yamada C., Mitsuzawa H., Shimizu T., Saito T., Smith K., Crouch E., Kuroki Y., Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry 2006 45 28 8657 8664 2-s2.0-33746047516 10.1021/bi060176z (Pubitemid 44078886)
134. Midwood K., Sacre S., Piccinini A. M., Inglis J., Trebaul A., Chan E., Drexler S., Sofat N., Kashiwagi M., Orend G., Brennan F., Foxwell B., Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nature Medicine 2009 15 7 774 780 2-s2.0-67650502739 10.1038/nm.1987
135. Piccinini A. M., Midwood K. S., Endogenous control of immunity against infection: tenascin-C regulates TLR4-mediated inflammation via microRNA-155. Cell Reports 2012 2 4 914 926 10.1016/j.celrep.2012.09.005
136. Sokolove J., Zhao X., Chandra P. E., Robinson W. H., Immune complexes containing citrullinated fibrinogen costimulate macrophages via toll-like receptor 4 and Fc γ receptor. Arthritis and Rheumatism 2011 63 1 53 62 2-s2.0-78650779270 10.1002/art.30081
137. Hodgkinson C. P., Patel K., Ye S., Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thrombosis and Haemostasis 2008 100 2 301 307 2-s2.0-48949097129 10.1160/TH08-03-0179
138. Lehmann S. M., Kruger C., Park B., Derkow K., Rosenberger K., Baumgart J., An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration. Nature Neuroscience 2012 15 6 827 835 10.1038/nn.3113
139. Rosenstiel P., Schreiber S., Kishore U., NOD-like receptors-pivotal guardians of the immunological integrity of barrier organs. Target Pattern Recognition in Innate Immunity 2009 Austin, Tex, USA Landes Bioscience 35 47
140. Langefeld T., Mohamed W., Ghai R., Chakraborty T., Kishore U., Toll-like receptors and NOD-like receptors: domain architecture and cellular signalling. Target Pattern Recognition in Innate Immunity 2009 Austin, Tex, USA Landes Bioscience 48 57
141. Kersse K., Bertrand M. J., Lamkanfi M., Vandenabeele P., NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine & Growth Factor Reviews 2011 22 5-6 257 276 10.1016/j.cytogfr.2011. 09.003
142. Bergsbaken T., Fink S. L., Cookson B. T., Pyroptosis: host cell death and inflammation. Nature Reviews Microbiology 2009 7 2 99 109 2-s2.0-58449083290 10.1038/nrmicro2070
143. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., Ferguson D. J. P., Campbell B. J., Jewell D., Simmons A., NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nature Medicine 2010 16 1 90 97 2-s2.0-73849151394 10.1038/nm.2069
144. Lei Y., Wen H., Yu Y., Taxman D. J., Zhang L., Widman D. G., The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012 36 6 933 946 10.1016/j.immuni.2012.03. 025
145. Masters S. L., Gerlic M., Metcalf D., Preston S., Pellegrini M., O'Donnell J. A., NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 2012 37 6 1009 1023 10.1016/j.immuni.2012.08.027
146. Lamkanfi M., Dixit V. M., Inflammasomes and their roles in health and disease. Annual Review of Cell and Developmental Biology 2012 28 137 161 10.1146/annurev-cellbio-101011-155745
147. Martinon F., Mayor A., Tschopp J., The inflammasomes: guardians of the body. Annual Review of Immunology 2009 27 229 265 2-s2.0-66749174867 10.1146/annurev.immunol.021908.132715
148. Agostini L., Martinon F., Burns K., McDermott M. F., Hawkins P. N., Tschopp J., NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004 20 3 319 325 2-s2.0-1642285783 10.1016/S1074-7613(04)00046-9 (Pubitemid 38388233)
149. Wen H., Ting J. P., O'Neill L. A., A role for the NLRP3 inflammasome in metabolic diseases-did warburg miss inflammation? Nature Immunology 2012 13 4 352 357 10.1038/ni.2228
150. Strowig T., Henao-Mejia J., Elinav E., Flavell R., Inflammasomes in health and disease. Nature 2012 481 7381 278 286 10.1038/nature10759
151. Mezzaroma E., Toldo S., Farkas D., Seropian I. M., Van Tassell B. W., Salloum F. N., The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proceedings of the National Academy of Sciences of the United States of America 2011 108 49 19725 19730 10.1073/pnas.1108586108
152. Shaw P. J., McDermott M. F., Kanneganti T. D., Inflammasomes and autoimmunity. Trends in Molecular Medicine 2011 17 2 57 64 2-s2.0-79651469172 10.1016/j.molmed.2010.11.001
153. dos Santos G., Kutuzov M. A., Ridge K. M., The inflammasome in lung diseases. American Journal of Physiology 2012 303 8 L627 L633 10.1152/ajplung.00225.2012
154. Kanneganti T. D., Central roles of NLRs and inflammasomes in viral infection. Nature Reviews Immunology 2010 10 10 688 698 2-s2.0-77957228318 10.1038/nri2851
155. Lamkanfi M., Dixit V. M., Modulation of inflammasome pathways by bacterial and viral pathogens. The Journal of Immunology 2011 187 2 596 602 2-s2.0-79960502623 10.4049/jimmunol.1100229
156. Halle A., Hornung V., Petzold G. C., Stewart C. R., Monks B. G., Reinheckel T., Fitzgerald K. A., Latz E., Moore K. J., Golenbock D. T., The NALP3 inflammasome is involved in the innate immune response to amyloid- β Nature Immunology 2008 9 8 857 865 2-s2.0-47849085872 10.1038/ni.1636
157. Jha S., Srivastava S. Y., Brickey W. J., Iocca H., Toews A., Morrison J. P., Chen V. S., Gris D., Matsushima G. K., Ting J. P. Y., The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. The Journal of Neuroscience 2010 30 47 15811 15820 2-s2.0-78649396261 10.1523/JNEUROSCI.4088-10.2010
158. Inoue M., Williams K. L., Gunn M. D., Shinohara M. L., NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2012 109 26 10480 10485 10.1073/pnas.1201836109
159. Inoue M., Williams K. L., Oliver T., Vandenabeele P., Rajan J. V., Miao E. A., Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Science Signaling 2012 5 225 ra38 10.1126/scisignal.2002767
160. De Rivero Vaccari J. P., Lotocki G., Alonso O. F., Bramlett H. M., Dietrich W. D., Keane R. W., Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism 2009 29 7 1251 1261 2-s2.0-67649360450 10.1038/jcbfm.2009.46
161. Abulafia D. P., De Rivero Vaccari J. P., Lozano J. D., Lotocki G., Keane R. W., Dietrich W. D., Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. Journal of Cerebral Blood Flow and Metabolism 2009 29 3 534 544 2-s2.0-61349152312 10.1038/jcbfm.2008.143
162. Hoegen T., Tremel N., Klein M., Angele B., Wagner H., Kirschning C., The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. The Journal of Immunology 2011 187 10 5440 5451 10.4049/jimmunol.1100790
163. Kaushik D. K., Gupta M., Kumawat K. L., Basu A., NLRP3 inflammasome: key mediator of neuroinflammation in murine japanese encephalitis. PLoS ONE 2012 7 2 e32270 10.1371/journal.pone.0032270
164. Zou J., Crews F. T., Inflammasome-IL-1 β signaling mediates ethanol inhibition of hippocampal neurogenesis. Frontiers in Neuroscience 2012 6 77 10.3389/fnins.2012.00077
165. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S., Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proceedings of the National Academy of Sciences of the United States of America 1979 76 1 333 337 2-s2.0-0009627006 (Pubitemid 9110191)
166. Godoy B., Murgas P., Tichauer J., Von Bernhardi R., Scavenger receptor class a ligands induce secretion of IL1 β and exert a modulatory effect on the inflammatory activation of astrocytes in culture. Journal of Neuroimmunology 2012 251 1-2 6 13 10.1016/j.jneuroim.2012.06.004
167. Mukhopadhyay S., Pluddemann A., Gordon S., Kishore U., Macrophage pattern recognition receptors in immunity, homeostasis and self tolerance. Target Pattern Recognition in Innate Immunity 2009 Austin, Tex, USA Landes Bioscience 1 14
168. Yamada Y., Doi T., Hamakubo T., Kodama T., Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cellular and Molecular Life Sciences 1998 54 7 628 640 2-s2.0-0031848185 10.1007/s000180050191 (Pubitemid 28379666)
169. Greaves D. R., Gordon S., The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. Journal of Lipid Research 2009 50 S282 S286 2-s2.0-66349136862 10.1194/jlr.R800066-JLR200
170. Wermeling F., Chen Y., Pikkarainen T., Scheynius A., Winqvist O., Izui S., Ravetch J. V., Tryggvason K., Karlsson M. C. I., Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. Journal of Experimental Medicine 2007 204 10 2259 2265 2-s2.0-34948820567 10.1084/jem.20070600 (Pubitemid 47529313)
171. Oquendo P., Hundt E., Lawler J., Seed B., CD36 directly mediates cytoadherence of plasmodium falciparum parasitized erythrocytes. Cell 1989 58 1 95 101 2-s2.0-0024395109 (Pubitemid 19180082)
172. Urban B. C., Ferguson D. J. P., Pain A., Willcox N., Plebanski M., Austyn J. M., Roberts D. J., Plasmodium falciparuminfected erythrocytes modulate the maturation of dendritic cells. Nature 1999 400 6739 73 77 2-s2.0-0033153766 10.1038/21900 (Pubitemid 29315113)
173. Urban B. C., Willcox N., Roberts D. J., A role for CD36 in the regulation of dendritic cell function. Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8750 8755 2-s2.0-0035902476 10.1073/pnas.151028698 (Pubitemid 32678099)
174. Stephen S. L., Freestone K., Dunn S., Twigg M. W., Homer-Vanniasinkam S., Walker J. H., Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. International Journal of Hypertension 2010 2010 21 646929 10.4061/2010/646929
175. Thakur S. A., Hamilton R. F., Holian A., Role of scavenger receptor a family in lung inflammation from exposure to environmental particles. Journal of Immunotoxicology 2008 5 2 151 157 2-s2.0-45849125790 10.1080/15476910802085863 (Pubitemid 351882420)
176. Wright A. K. A., Rao S., Range S., Eder C., Hofer T. P. J., Frankenberger M., Kobzik L., Brightling C., Grigg J., Ziegler-Heitbrock L., Pivotal advance: expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. Journal of Leukocyte Biology 2009 86 3 479 489 2-s2.0-70149103589 10.1189/jlb.1108699
177. El Khoury J., Hickman S. E., Thomas C. A., Cao L., Silverstein S. C., Loike J. D., Scavenger receptor-mediated adhesion of microglia to β -amyloid fibrils. Nature 1996 382 6593 716 719 2-s2.0-0029787599 10.1038/382716a0 (Pubitemid 26282177)
178. Christie R. H., Freeman M., Hyman B. T., Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. The American Journal of Pathology 1996 148 2 399 403 2-s2.0-0030039871 (Pubitemid 26056725)
179. Xu Y., Qian L., Zong G., Ma K., Zhu X., Zhang H., Class A scavenger receptor promotes cerebral ischemic injury by pivoting microglia/macrophage polarization. Neuroscience 2012 218 35 48 10.1016/j.neuroscience.2012.05.036
180. + T-cells proliferation in EAE mouse model. Journal of Neuroinflammation 2012 9 120 10.1186/1742-2094-9- 120
181. Huang F., Buttini M., Wyss-Coray T., McConlogue L., Kodama T., Pitas R. E., Mucke L., Elimination of the class a scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. The American Journal of Pathology 1999 155 5 1741 1747 2-s2.0-0032732224
182. Husemann J., Silverstein S. C., Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. The American Journal of Pathology 2001 158 3 825 832 2-s2.0-0035101055 (Pubitemid 32221775)
183. Srivastava R. A. K., Jain J. C., Scavenger receptor class B type I expression and elemental analysis in cerebellum and parietal cortex regions of the Alzheimer's disease brain. Journal of the Neurological Sciences 2002 196 1-2 45 52 2-s2.0-0037090595 10.1016/S0022-510X(02)00026-6 (Pubitemid 34311540)
184. Thanopoulou K., Fragkouli A., Stylianopoulou F., Georgopoulos S., Scavenger receptor class B type i (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proceedings of the National Academy of Sciences of the United States of America 2010 107 48 20816 20821 2-s2.0-78650527026 10.1073/pnas.1005888107
185. Park L., Wang G., Zhou P., Zhou J., Pitstick R., Previti M. L., Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid- β Proceedings of the National Academy of Sciences of the United States of America 2011 108 12 5063 5068 10.1073/pnas.1015413108
186. Park L., Zhou J., Zhou P., Pistick R., El Jamal S., Younkin L., Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proceedings of the National Academy of Sciences of the United States of America 2013 110 8 3089 3094 10.1073/pnas.1300021110
187. Shi D. Y., Bierhaus A., Nawroth P. P., Stern D. M., RAGE and Alzheimer's disease: a progression factor for amyloid- β-induced cellular perturbation? Journal of Alzheimer's Disease 2009 16 4 833 843 2-s2.0-67649739088 10.3233/JAD-2009-1030
188. Fang, Lue L. F., Yan S., Xu H., Luddy J. S., Chen D., Walker D. G., Stern D. M., Yan S., Schmidt A. M., Chen J. X., Yan S. S., RAGE-dependent signaling in microglia contributes to neuroinflammation, A β accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. The FASEB Journal 2010 24 4 1043 1055 2-s2.0-77951647591 10.1096/fj.09-139634
189. Origlia N., Righi M., Capsoni S., Cattaneo A., Fang F., Stern D. M., Chen J. X., Schmidt A. M., Arancio O., Shi D. Y., Domenici L., Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid- β -mediated cortical synaptic dysfunction. The Journal of Neuroscience 2008 28 13 3521 3530 2-s2.0-41549089757 10.1523/JNEUROSCI.0204-08.2008 (Pubitemid 351469321)
190. Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A., McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D., Hori O., Ogawa S., Stern D. M., Yamada K., Yan S. S., RAGE-mediated signaling contributes to intraneuronal transport of amyloid- β and neuronal dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2009 106 47 20021 20026 2-s2.0-73949088883 10.1073/pnas.0905686106
191. Porter R. R., Reid K. B. M., Activation of the complement system by antibody-antigen complexes: the classical pathway. Advances in Protein Chemistry 1979 33 1 71 2-s2.0-0018590717 10.1016/S0065-3233(08)60458-1
192. Dahl M. R., Thiel S., Matsushita M., Fujita T., Willis A. C., Christensen T., Vorup-Jensen T., Jensenius J. C., MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001 15 1 127 135 2-s2.0-0034897825 10.1016/S1074-7613(01)00161-3 (Pubitemid 32728326)
193. Thiel S., Vorup-Jensen T., Stover C. M., Schwaeble W., Laursen S. B., Poulsen K., Willis A. C., Eggleton P., Hansen S., Holmskov U., Reid K. B. M., Jensenius J. C., A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997 386 6624 506 510 2-s2.0-0030950185 10.1038/386506a0 (Pubitemid 27164078)
194. Carroll M. V., Sim R. B., Complement in health and disease. Advanced Drug Delivery Reviews 2011 63 12 965 975 10.1016/j.addr.2011.06.005
195. Kang Y. H., Tan L. A., Carroll M. V., Gentle M. E., Sim R. B., Target pattern recognition by complement proteins of the classical and alternative pathways. Advances in Experimental Medicine and Biology 2009 653 117 128 2-s2.0-70349598981 10.1007/978-1-4419-0901-5-8
196. Thiel S., Gadjeva M., Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Advances in Experimental Medicine and Biology 2009 653 58 73 2-s2.0-70350490533 10.1007/978-1-4419-0901-5-5
197. Reid K. B., Porter R. R., The proteolytic activation systems of complement. Annual Review of Biochemistry 1981 50 433 464 2-s2.0-0019364862
198. Hajishengallis G., Lambris J. D., Crosstalk pathways between toll-like receptors and the complement system. Trends in Immunology 2010 31 4 154 163 2-s2.0-77950187449 10.1016/j.it.2010.01.002
199. Carroll M. C., Isenman D. E., Regulation of humoral immunity by complement. Immunity 2012 37 2 199 207 10.1016/j.immuni.2012.08.002
200. Petersen S. V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., Jensenius J. C., Control of the classical and the MBL pathway of complement activation. Molecular Immunology 2001 37 14 803 811 2-s2.0-0035099159 10.1016/S0161-5890(01) 00004-9 (Pubitemid 32226376)
201. Zipfel P. F., Skerka C., Complement regulators and inhibitory proteins. Nature Reviews Immunology 2009 9 10 729 740 2-s2.0-70349437186 10.1038/nri2620
202. Kishore U., Sim R. B., Factor H as a regulator of the classical pathway activation. Immunobiology 2012 217 2 162 168 10.1016/j.imbio.2011.07.024
203. Tan L. A., Yang A. C., Kishore U., Sim R. B., Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway. Protein & Cell 2011 2 4 320 332 10.1007/s13238-011-1029-y
204. Tan L. A., Yu B., Sim F. C. J., Kishore U., Sim R. B., Complement activation by phospholipids: the interplay of factor H and C1q. Protein & Cell 2010 1 11 1033 1049 2-s2.0-79952598239 10.1007/s13238-010-0125-8
205. Kang Y. H., Urban B. C., Sim R. B., Kishore U., Human complement factor H modulates C1q-mediated phagocytosis of apoptotic cells. Immunobiology 2012 217 4 455 464 10.1016/j.imbio.2011.10.008
206. Walker D. G., McGeer P. L., Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin. Neuroscience Letters 1993 157 1 99 102 2-s2.0-0027208722 10.1016/0304-3940(93)90652-2 (Pubitemid 23213065)
207. Walker D. G., Yasuhara O., Patston P. A., McGeer E. G., McGeer P. L., Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Research 1995 675 1-2 75 82 2-s2.0-0028918713 10.1016/0006-8993(95)00041-N
208. Veerhuis R., Janssen I., Hoozemans J. J. M., De Groot C. J. A., Hack C. E., Eikelenboom P., Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathologica 1998 96 3 287 296 2-s2.0-0031691401 10.1007/s004010050896 (Pubitemid 28419847)
209. Thomas A., Gasque P., Vaudry D., Gonzalez B., Fontaine M., Expression of a complete and functional complement system by human neuronal cells in vitro. International Immunology 2000 12 7 1015 1023 2-s2.0-0033880688 (Pubitemid 30599354)
210. Barnum S. R., Jones J. L., Benveniste E. N., Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene expression in human astroglioma cells. Glia 1993 7 3 225 236 2-s2.0-0027566452
211. Gasque P., Chan P., Mauger C., Schouft M. T., Singhrao S., Dierich M. P., Morgan B. P., Fontaine M., Identification and characterization of complement C3 receptors on human astrocytes. The Journal of Immunology 1996 156 6 2247 2255 2-s2.0-0029979527 (Pubitemid 26087455)
212. Walker D. G., Kim S. U., McGeer P. L., Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. The Journal of Neuroscience Research 1995 40 4 478 493 2-s2.0-0028923898 10.1002/jnr.490400407
213. Veerhuis R., Janssen I., De Groot C. J. A., Van Muiswinkel F. L., Hack C. E., Eikelenboom P., Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Experimental Neurology 1999 160 1 289 299 2-s2.0-0032710620 10.1006/exnr.1999.7199
214. Gasque P., Singhrao S. K., Neal J. W., Wang P., Sayah S., Fontaine M., Morgan B. P., The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. The Journal of Immunology 1998 160 7 3543 3554 2-s2.0-0032055221 (Pubitemid 28164750)
215. Rahpeymai Y., Hietala M. A., Wilhelmsson U., Fotheringham A., Davies I., Nilsson A. K., Zwirner J., Wetsel R. A., Gerard C., Pekny M., Pekna M., Complement: a novel factor in basal and ischemia-induced neurogenesis. The EMBO Journal 2006 25 6 1364 1374 2-s2.0-33645309347 10.1038/sj.emboj.7601004
216. Moriyama M., Fukuhara T., Britschgi M., He Y., Narasimhan R., Villeda S., Molina H., Huber B. T., Holers M., Wyss-Coray T., Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. The Journal of Neuroscience 2011 31 11 3981 3989 2-s2.0-79952751974 10.1523/JNEUROSCI.3617-10.2011
217. Stephan A. H., Barres B. A., Stevens B., The complement system: an unexpected role in synaptic pruning during development and disease. Annual Review of Neuroscience 2012 35 369 389 10.1146/annurev-neuro-061010-113810
218. Boulanger L. M., Immune proteins in brain development and synaptic plasticity. Neuron 2009 64 1 93 109 2-s2.0-70349794451 10.1016/j.neuron.2009.09. 001
219. Stevens B., Allen N. J., Vazquez L. E., Howell G. R., Christopherson K. S., Nouri N., Micheva K. D., Mehalow A. K., Huberman A. D., Stafford B., Sher A., Litke A., Lambris J. D., Smith S. J., John S. W. M., Barres B. A., The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 6 1164 1178 2-s2.0-36849076770 10.1016/j.cell.2007.10.036 (Pubitemid 350235022)
220. Nayak A., Ferluga J., Tsolaki A. G., Kishore U., The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunology Letters 2010 131 2 139 150 2-s2.0-77953712553 10.1016/j.imlet.2010. 03.012
221. Chu Y., Jin X., Parada I., Pesic A., Stevens B., Barres B., Prince D. A., Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proceedings of the National Academy of Sciences of the United States of America 2010 107 17 7975 7980 2-s2.0-77952403414 10.1073/pnas.0913449107
222. Benoit M. E., Tenner A. J., Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. The Journal of Neuroscience 2011 31 9 3459 3469 2-s2.0-79952273376 10.1523/JNEUROSCI.3932-10.2011
223. Bénard M., Raoult E., Vaudry D., Leprince J., Falluel-Morel A., Gonzalez B. J., Galas L., Vaudry H., Fontaine M., Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Molecular Immunology 2008 45 14 3767 3774 2-s2.0-48049098994 10.1016/j.molimm.2008.05.027
224. Van Beek J., Nicole O., Ali C., Ischenko A., MacKenzie E. T., Buisson A., Fontaine M., Complement anaphylatoxin c3a is selectively protective against nmda-induced neuronal cell death. NeuroReport 2001 12 2 289 293 2-s2.0-0035847643 (Pubitemid 32114367)
225. Osaka H., Mukherjee P., Aisen P. S., Pasinetti G. M., Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. Journal of Cellular Biochemistry 1999 73 3 303 311 (Pubitemid 29198005)
226. Mukherjee P., Pasinetti G. M., Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. Journal of Neurochemistry 2001 77 1 43 49 2-s2.0-0035076597 10.1046/j.1471-4159. 2001.00167.x (Pubitemid 32245078)
227. Mukherjee P., Thomas S., Pasinetti G. M., Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. Journal of Neuroinflammation 2008 5, article 5 2-s2.0-39649121460 10.1186/1742-2094-5-5 (Pubitemid 351285320)
228. Ram S., Lewis L. A., Rice P. A., Infections of people with complement deficiencies and patients who have undergone splenectomy. Clinical Microbiology Reviews 2010 23 4 740 780 2-s2.0-78049408075 10.1128/CMR.00048-09
229. Kugelberg E., Gollan B., Tang C. M., Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 2008 26 8 I34 I39 2-s2.0-57749195313 10.1016/j.vaccine.2008.11.059
230. Schneider M. C., Exley R. M., Chan H., Feavers I., Kang Y. H., Sim R. B., Tang C. M., Functional significance of factor H binding to Neisseria meningitidis. The Journal of Immunology 2006 176 12 7566 7575 2-s2.0-33744933451 (Pubitemid 43849060)
231. Schneider M. C., Prosser B. E., Caesar J. J. E., Kugelberg E., Li S., Zhang Q., Quoraishi S., Lovett J. E., Deane J. E., Sim R. B., Roversi P., Johnson S., Tang C. M., Lea S. M., Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009 458 7240 890 893 2-s2.0-67249113222 10.1038/nature07769
232. Bathum L., Hansen H., Teisner B., Koch C., Garred P., Rasmussen K., Wang P., Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Molecular Immunology 2006 43 5 473 479 2-s2.0-28444439924 10.1016/j.molimm.2005.02.017 (Pubitemid 41740436)
233. Rupprecht T. A., Angele B., Klein M., Heesemann J., Pfister H. W., Botto M., Koedel U., Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. The Journal of Immunology 2007 178 3 1861 1869 2-s2.0-33846504078 (Pubitemid 46154659)
234. Wooster D. G., Maruvada R., Blom A. M., Prasadarao N. V., Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology 2006 117 4 482 493 2-s2.0-33645021029 10.1111/j.1365-2567.2006.02323.x
235. Stoermer K. A., Morrison T. E., Complement and viral pathogenesis. Virology 2011 411 2 362 373 2-s2.0-79952073504 10.1016/j.virol.2010.12.045
236. Kapadia S. B., Levine B., Speck S. H., Virgin H. W., Critical role of complement and viral evasion of complement in acute, persistent, and latent γ -herpesvirus infection. Immunity 2002 17 2 143 155 2-s2.0-0036669274 10.1016/S1074-7613(02)00369-2 (Pubitemid 35245957)
237. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., Diamond M. S., Complement activation is required for induction of a protective antibody response against west nile virus infection. Journal of Virology 2005 79 12 7466 7477 2-s2.0-19944405462 10.1128/JVI.79.12.7466-7477.2005 (Pubitemid 40756783)
238. Fuchs A., Pinto A. K., Schwaeble W. J., Diamond M. S., The lectin pathway of complement activation contributes to protection from west nile virus infection. Virology 2011 412 1 101 109 2-s2.0-79952535868 10.1016/j.virol.2011. 01.003
239. Libbey J. E., Kirkman N. J., Wilcox K. S., White H. S., Fujinami R. S., Role for complement in the development of seizures following acute viral infection. Journal of Virology 2010 84 13 6452 6460 2-s2.0-77953308841 10.1128/JVI.00422-10
240. Singh K. K., Nathamu S., Adame A., Alire T. U., Dumaop W., Gouaux B., Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehavioral HIV Medicine 2011 3 41 52
241. Rambach G., Maier H., Vago G., Mohsenipour I., Lass-Flörl C., Defant A., Würzner R., Dierich M. P., Speth C., Complement induction and complement evasion in patients with cerebral aspergillosis. Microbes and Infection 2008 10 14-15 1567 1576 2-s2.0-56949100642 10.1016/j.micinf.2008.09. 011
242. Rambach G., Dum D., Mohsenipour I., Hagleitner M., Würzner R., Lass-Flörl C., Speth C., Secretion of a fungal protease represents a complement evasion mechanism in cerebral aspergillosis. Molecular Immunology 2010 47 7-8 1438 1449 2-s2.0-77950619363 10.1016/j.molimm.2010.02.010
243. Speth C., Rambach G., Complement attack against aspergillus and corresponding evasion mechanisms. Interdisciplinary Perspectives on Infectious Diseases 2012 2012 9 463794 10.1155/2012/463794
244. Lackner P., Hametner C., Beer R., Burger C., Broessner G., Helbok R., Speth C., Schmutzhard E., Complement factors C1q, C3 and C5 in brain and serum of mice with cerebral malaria. Malaria Journal 2008 7, article 207 2-s2.0-54449093537 10.1186/1475-2875-7-207
245. Ramos T. N., Darley M. M., Hu X., Billker O., Rayner J. C., Ahras M., Wohler J. E., Barnum S. R., Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria. The Journal of Immunology 2011 186 12 6657 6660 2-s2.0-79959566616 10.4049/jimmunol.1100603
246. Mitchell D. A., Kirby L., Paulin S. M., Villiers C. L., Sim R. B., Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue. Molecular Immunology 2007 44 11 2997 3004 2-s2.0-33947145602 10.1016/j.molimm.2006.12.027 (Pubitemid 46412484)
247. Sim R. B., Kishore U., Villiers C. L., Marche P. N., Mitchell D. A., C1q binding and complement activation by prions and amyloids. Immunobiology 2007 212 4-5 355 362 2-s2.0-34249679205 10.1016/j.imbio.2007.04.001 (Pubitemid 46825245)
248. Ishii T., Haga S., Yagishita S., Tateishi J., The presence of complements in amyloid plaques of creutzfeldt-Jakob disease and gerstmann-straussler- scheinker disease. Applied Pathology 1984 2 6 370 379 2-s2.0-0021543112 (Pubitemid 16028901)
249. Kovacs G. G., Gasque P., Ströbel T., Lindeck-Pozza E., Strohschneider M., Ironside J. W., Budka H., Guentchev M., Complement activation in human prion disease. Neurobiology of Disease 2004 15 1 21 28 2-s2.0-1642456624 10.1016/j.nbd.2003.09.010 (Pubitemid 38134377)
250. Bellander B. M., Olafsson I. H., Ghatan P. H., Bro Skejo H. P., Hansson L. O., Wanecek M., Svensson M. A., Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochirurgica 2011 153 1 90 100 2-s2.0-78651251701 10.1007/s00701-010-0737-z
251. Bellander B. M., Singhrao S. K., Ohlsson M., Mattsson P., Svensson M., Complement activation in the human brain after traumatic head injury. Journal of Neurotrauma 2001 18 12 1295 1311 2-s2.0-0035669691 (Pubitemid 34038404)
252. Stahel P. F., Morganti-Kossmann M. C., Perez D., Redaelli C., Gloor B., Trentz O., Kossmann T., Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. Journal of Neurotrauma 2001 18 8 773 781 2-s2.0-0034888513 (Pubitemid 32769773)
253. Stahel P. F., Flierl M. A., Morgan B. P., Persigehl I., Stoll C., Conrad C., Touban B. M., Smith W. R., Beauchamp K., Schmidt O. I., Ertel W., Leinhase I., Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. Journal of Neuroinflammation 2009 6, article 2 2-s2.0-60649094952 10.1186/1742-2094-6-2
254. Rancan M., Morganti-Kossmann M. C., Barnum S. R., Saft S., Schmidt O. I., Ertel W., Stahel P. F., Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. Journal of Cerebral Blood Flow and Metabolism 2003 23 9 1070 1074 2-s2.0-0041835960 (Pubitemid 37082432)
255. Yanamadala V., Friedlander R. M., Complement in neuroprotection and neurodegeneration. Trends in Molecular Medicine 2010 16 2 69 76 2-s2.0-76349084466 10.1016/j.molmed.2009.12.001
256. Komotar R. J., Kim G. H., Otten M. L., Hassid B., Mocco J., Sughrue M. E., Starke R. M., MacK W. J., Ducruet A. F., Merkow M. B., Garrett M. C., Connolly E. S., The role of complement in stroke therapy. Advances in Experimental Medicine and Biology 2008 632 23 33 2-s2.0-58149334965
257. Di Napoli M., Early inflammatory response in ischemic stroke. Thrombosis Research 2001 103 3 261 264 2-s2.0-0035424113 10.1016/S0049-3848(01)00290-0 (Pubitemid 32728111)
258. Arumugam T. V., Shiels I. A., Woodruff T. M., Granger D. N., Taylor S. M., The role of the complement system in ischemia-reperfusion injury. Shock 2004 21 5 401 409 2-s2.0-4043106052
259. Pavlovski D., Thundyil J., Monk P. N., Wetsel R. A., Taylor S. M., Woodruff T. M., Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. The FASEB Journal 2012 26 9 3680 3690 10.1096/fj.11-202382
260. Cervera A., Planas A. M., Justicia C., Urra X., Jensenius J. C., Torres F., Lozano F., Chamorro A., Genetically-defined deficiency of mannose-binding
261. Pedersen E. D., Løberg E. M., Vege E., Daha M. R., Mæhlen J., Mollnes T. E., In situ deposition of complement in human acute brain ischaemia. Scandinavian Journal of Immunology 2009 69 6 555 562 2-s2.0-65349162764 10.1111/j.1365-3083.2009.02253.x
262. Arumugam T. V., Tang S. C., Lathia J. D., Cheng A., Mughal M. R., Chigurupati S., Magnus T., Chan S. L., Jo D. G., Ouyang X., Fairlie D. P., Granger D. N., Vortmeyer A., Basta M., Mattson M. P., Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proceedings of the National Academy of Sciences of the United States of America 2007 104 35 14104 14109 2-s2.0-35348848463 10.1073/pnas.0700506104 (Pubitemid 350003342)
263. Mocco J., Mack W. J., Ducruet A. F., Sosunov S. A., Sughrue M. E., Hassid B. G., Nair M. N., Laufer I., Komotar R. J., Holland M. C. H., Pinsky D. J., Connolly E. S., Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circulation Research 2006 99 2 209 217 2-s2.0-33747598070 10.1161/01.RES.0000232544.90675.42 (Pubitemid 44297045)
264. Heimann A., Takeshima T., Horstick G., Kempski O., C1-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Research 1999 838 1-2 210 213 2-s2.0-0033554228 10.1016/S0006-8993(99)01740-0 (Pubitemid 29389837)
265. Arumugam T. V., Woodruff T. M., Lathia J. D., Selvaraj P. K., Mattson M. P., Taylor S. M., Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009 158 3 1074 1089 2-s2.0-59349097661 10.1016/j.neuroscience.2008.07.015
266. Bonifati D. M., Kishore U., Role of complement in neurodegeneration and neuroinflammation. Molecular Immunology 2007 44 5 999 1010 2-s2.0-33748780095 10.1016/j.molimm.2006.03.007 (Pubitemid 44414994)
267. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., Lieberburg I., Complement activation by β -amyloid in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1992 89 21 10016 10020 2-s2.0-0026447529 10.1073/pnas.89.21.10016
268. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C., Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Archiv Abteilung B Cell Pathology 1989 56 4 259 262 2-s2.0-0024543574 (Pubitemid 19049180)
269. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G., Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neuroscience Letters 1989 107 1-3 341 346 2-s2.0-0024317005 10.1016/0304-3940(89)90843-4 (Pubitemid 20013261)
270. Webster S., Bonnell B., Rogers J., Charge-based binding of complement component C1q to the Alzheimer amyloid β -peptide. The American Journal of Pathology 1997 150 5 1531 1536 2-s2.0-0030978135 (Pubitemid 27193802)
271. Kishore U., Gupta S. K., Perdikoulis M. V., Kojouharova M. S., Urban B. C., Reid K. B. M., Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. The Journal of Immunology 2003 171 2 812 820 2-s2.0-0038783609 (Pubitemid 36871392)
272. Webster S. D., Yang A. J., Margol L., Garzon-Rodriguez W., Glabe C. G., Tenner A. J., Complement component C1q modulates the phagocytosis of A β by microglia. Experimental Neurology 2000 161 1 127 138 2-s2.0-0034050540 10.1006/exnr.1999.7260 (Pubitemid 30136535)
273. Fan R., Tenner A. J., Complement C1q expression induced by A β in rat hippocampal organotypic slice cultures. Experimental Neurology 2004 185 2 241 253 2-s2.0-0347004457 10.1016/j.expneurol.2003.09.023 (Pubitemid 38084850)
274. Sarvari M., Vago I., Weber C. S., Nagy J., Gal P., Mak M., Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. Journal of Neuroimmunology 2003 137 1-2 12 18 10.1016/S0165-5728(03) 00040-7 (Pubitemid 36351561)
275. Fonseca M. I., Zhou J., Botto M., Tenner A. J., Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. The Journal of Neuroscience 2004 24 29 6457 6465 2-s2.0-3242766671 10.1523/JNEUROSCI.0901-04.2004 (Pubitemid 38971692)
276. Strohmeyer R., Shen Y., Rogers J., Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Molecular Brain Research 2000 81 1-2 7 18 2-s2.0-0034734786 10.1016/S0169-328X(00)00149-2
277. Strohmeyer R., Ramirez M., Cole G. J., Mueller K., Rogers J., Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. Journal of Neuroimmunology 2002 131 1-2 135 146 2-s2.0-0036789954 10.1016/S0165-5728(02)00272-2
278. Trouw L. A., Nielsen H. M., Minthon L., Londos E., Landberg G., Veerhuis R., Janciauskiene S., Blom A. M., C4b-binding protein in Alzheimer's disease: binding to A β 1-42 and to dead cells. Molecular Immunology 2008 45 13 3649 3660 2-s2.0-46749123000 10.1016/j.molimm.2008.04.025
279. Haga S., Akai K., Ishii T., Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathologica 1989 77 6 569 575 2-s2.0-0024573330 (Pubitemid 19125369)
280. Korotzer A. R., Watt J., Cribbs D., Tenner A. J., Burdick D., Glabe C., Cotman C. W., Cultured rat microglia express C1q and receptor for C1q: implications for amyloid effects on microglia. Experimental Neurology 1995 134 2 214 221 2-s2.0-0028805371 10.1006/exnr.1995.1051
281. McGeer P. L., McGeer E. G., The possible role of complement activation in Alzheimer disease. Trends in Molecular Medicine 2002 8 11 519 523 2-s2.0-0036841667 10.1016/S1471-4914(02)02422-X (Pubitemid 35264964)
282. Sokolowski J. D., Mandell J. W., Phagocytic clearance in neurodegeneration. The American Journal of Pathology 2011 178 4 1416 1428 10.1016/j.ajpath.2010.12.051
283. Maier M., Peng Y., Jiang L., Seabrook T. J., Carroll M. C., Lemere C. A., Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. The Journal of Neuroscience 2008 28 25 6333 6341 2-s2.0-46749087854 10.1523/JNEUROSCI.0829-08.2008
284. Wyss-Coray T., Yan F., Lin A. H. T., Lambris J. D., Alexander J. J., Quigg R. J., Masliah E., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10837 10842 2-s2.0-0036679142 10.1073/pnas.162350199
285. Zhou J., Fonseca M. I., Pisalyaput K., Tenner A. J., Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. Journal of Neurochemistry 2008 106 5 2080 2092 2-s2.0-49549095792 10.1111/j.1471-4159.2008.05558.x
286. Britschgi M., Takeda-Uchimura Y., Rockenstein E., Johns H., Masliah E., Wyss-Coray T., Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice. Journal of Neuroinflammation 2012 9 220 10.1186/1742-2094-9-220
287. Lambert J. C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M. J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fiévet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., De Pancorbo M. M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Boss P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanché H., Dartigues J. F., Tzourio C., Gut I., Van Broeckhoven C., Alpérovitch A., Lathrop M., Amouyel P., Arosio B., Coto E., Zompo M. D., Deramecourt V., Epelbaum J., Forti P., Brice A., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Ravaglia G., Sahel J., Valdivieso F., Vepsäläinen S., Pilotto A., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 2009 41 10 1094 1099 2-s2.0-78549264026 10.1038/ng.439
288. Lukiw W. J., Surjyadipta B., Dua P., Alexandrov P. N., Common micro RNAs (miRNAs) target complement factor H, (CFH) regulation in alzheimer's disease (AD) and in age-related macular degeneration (AMD). International Journal of Biochemistry and Molecular Biology 2012 3 1 105 116
289. Ingram G., Hakobyan S., Robertson N. P., Morgan B. P., Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 2009 155 2 128 139 2-s2.0-58149277249 10.1111/j.1365-2249.2008.03830.x
290. Barnett M. H., Parratt J. D. E., Cho E. S., Prineas J. W., Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of Neurology 2009 65 1 32 46 2-s2.0-60849102769 10.1002/ana.21524
291. Ramaglia V., Hughes T. R., Donev R. M., Ruseva M. M., Wu X., Huitinga I., C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2012 109 3 965 970 10.1073/pnas.1111924109
292. Ingram G., Hakobyan S., Hirst C. L., Harris C. L., Pickersgill T. P., Cossburn M. D., Loveless S., Robertson N. P., Morgan B. P., Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010 133 6 1602 1611 2-s2.0-77952991177 10.1093/brain/awq085
293. Compston D. A. S., Morgen B. P., Campbell A. K., Wilkins P., Cole G., Thomas N. D., Jasani B., Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathology and Applied Neurobiology 1989 15 4 307 316 2-s2.0-0024353096 (Pubitemid 19208151)
294. Prineas J. W., Kwon E. E., Cho E. S., Sharer L. R., Barnett M. H., Oleszak E. L., Hoffman B., Morgan B. P., Immunopathology of secondary- progressive multiple sclerosis. Annals of Neurology 2001 50 5 646 657 2-s2.0-0034765063 10.1002/ana.1255 (Pubitemid 33021923)
295. Brink B. P., Veerhuis R., Breij E. C. W., Van Der Valk P., Dijkstra C. D., Bö L., The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. Journal of Neuropathology and Experimental Neurology 2005 64 2 147 155 2-s2.0-14844293538 (Pubitemid 40349313)
296. Breij E. C. W., Brink B. P., Veerhuis R., Van Den Berg C., Vloet R., Yan R., Dijkstra C. D., Van Der Valk P., Bö L., Homogeneity of active demyelinating lesions in established multiple sclerosis. Annals of Neurology 2008 63 1 16 25 2-s2.0-39049163500 10.1002/ana.21311 (Pubitemid 351240547)
297. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
298. McGeer P. L., McGeer E. G., Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders 2004 10 1 S3 S7 2-s2.0-1942454250 10.1016/j.parkreldis.2004.01.005 (Pubitemid 38510423)
299. Yamada T., McGeer P. L., McGeer E. G., Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathologica 1992 84 1 100 104 2-s2.0-0026680616 10.1007/BF00427222
300. Loeffler D. A., Camp D. M., Conant S. B., Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. Journal of Neuroinflammation 2006 3, article 29 2-s2.0-33750802218 10.1186/1742-2094-3-29 (Pubitemid 44712385)
301. Wang Y., Hancock A. M., Bradner J., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Kim H. M., Leverenz J. B., Montine T. J., Ginghina C., Edwards K. L., Snapinn K. W., Goldstein D. S., Shi M., Zhang J., Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. The American Journal of Pathology 2011 178 4 1509 1516 2-s2.0-79953667345 10.1016/j.ajpath.2011.01. 006
302. Hirsch E., Graybiel A. M., Agid Y. A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988 334 6180 345 348 2-s2.0-0023740954
303. Zhang W., Phillips K., Wielgus A. R., Liu J., Albertini A., Zucca F. A., Faust R., Qian S. Y., Miller D. S., Chignell C. F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J. S., Sulzer D., Zecca L., Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of parkinson's disease. Neurotoxicity Research 2011 19 1 63 72 2-s2.0-78650527643 10.1007/s12640-009-9140-z
304. Depboylu C., Schäfer M. K. H., Arias-Carrión O., Oertel W. H., Weihe E., Höglinger G. U., Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. Journal of Neuropathology and Experimental Neurology 2011 70 2 125 132 2-s2.0-79251600760 10.1097/NEN.0b013e31820805b9
305. MacDonald M. E., Ambrose C. M., Duyao M. P., Myers R. H., Lin C., Srinidhi L., Barnes G., Taylor S. A., James M., Groot N., MacFarlane H., Jenkins B., Anderson M. A., Wexler N. S., Gusella J. F., Bates G. P., Baxendale S., Hummerich H., Kirby S., A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993 72 6 971 983 2-s2.0-0027480960 10.1016/0092-8674(93)90585-E (Pubitemid 23110238)
306. Singhrao S. K., Neal J. W., Morgan B. P., Gasque P., Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Experimental Neurology 1999 159 2 362 376 2-s2.0-0032873347 10.1006/exnr.1999.7170 (Pubitemid 29485223)
307. Hakobyan S., Boyajyan A., Sim R. B., Classical pathway complement activity in schizophrenia. Neuroscience Letters 2005 374 1 35 37 2-s2.0-14544299356 10.1016/j.neulet.2004.10.024 (Pubitemid 41556543)
308. Arakelyan A., Zakharyan R., Khoyetsyan A., Poghosyan D., Aroutiounian R., Mrazek F., Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia. BMC Clinical Pathology 11 10
309. Mayilyan K. R., Dodds A., Boyajyan A. S., Soghoyan A. F., Sim R. B., Complement C4B protein in schizophrenia. World Journal of Biological Psychiatry 2008 9 3 225 230 2-s2.0-48249100020 10.1080/15622970701227803
310. Boyajyan A., Khoyetsyan A., Chavushyan A., Alternative complement pathway in schizophrenia. Neurochemical Research 2010 35 6 894 898 2-s2.0-77953232938 10.1007/s11064-010-0126-2
311. Mayilyan K. R., Arnold J. N., Presanis J. S., Soghoyan A. F., Sim R. B., Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neuroscience Letters 2006 404 3 336 341 2-s2.0-33746279078 10.1016/j.neulet.2006.06.051 (Pubitemid 44108442)
312. Mayilyan K. R., Weinberger D. R., Sim R. B., The complement system in schizophrenia. Drug News and Perspectives 2008 21 4 200 210 2-s2.0-51349111299 10.1358/dnp.2008.21.4.1213349
313. Zakharyan R., Khoyetsyan A., Arakelyan A., Boyajyan A., Gevorgyan A., Stahelova A., Association of C1QB gene polymorphism with schizophrenia in armenian population. BMC Medical Genetics 2011 12 126 10.1186/1471-2350-12-126
314. Håvik B., Le Hellard S., Rietschel M., Lybæk H., Djurovic S., Mattheisen M., Mhleisen T. W., Degenhardt F., Priebe L., Maier W., Breuer R., Schulze T. G., Agartz I., Melle I., Hansen T., Bramham C. R., Nthen M. M., Stevens B., Werge T., Andreassen O. A., Cichon S., Steen V. M., The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. Biological Psychiatry 2011 70 1 35 42 2-s2.0-79958839837 10.1016/j.biopsych.2011.01.030
315. Rudduck C., Beckman L., Franzen G., Lindstrom L., C3 and C6 complement types in schizophrenia. Human Heredity 1985 35 4 255 258 2-s2.0-0021966939 (Pubitemid 15233446)
316. Rudduck C., Beckman L., Franzen G., Lindstrom L., C3 and C6 complement types in schizophrenia. Human Heredity 1985 35 4 255 258 10.1159/000153555 (Pubitemid 15233446)
317. Renton A. E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J. R., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 72 2 257 268 10.1016/j.neuron.2011. 09.010
318. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011 72 2 245 256
319. Shastri A., Bonifati D. M., Kishore U., Kishore U., Other Dementias. Neurodegenerative Diseases 2013 InTech. http://www.intechopen.com/books/ neurodegenerative-diseases/other-dementias